PL443815A1 - Solid oral preparation of vitamins B containing a stabilized composition of vitamin B12 and method of its preparation - Google Patents
Solid oral preparation of vitamins B containing a stabilized composition of vitamin B12 and method of its preparationInfo
- Publication number
- PL443815A1 PL443815A1 PL443815A PL44381521A PL443815A1 PL 443815 A1 PL443815 A1 PL 443815A1 PL 443815 A PL443815 A PL 443815A PL 44381521 A PL44381521 A PL 44381521A PL 443815 A1 PL443815 A1 PL 443815A1
- Authority
- PL
- Poland
- Prior art keywords
- vitamin
- preparation
- vitamins
- solid oral
- stabilized composition
- Prior art date
Links
- 229930003779 Vitamin B12 Natural products 0.000 title abstract 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title abstract 4
- 235000019163 vitamin B12 Nutrition 0.000 title abstract 4
- 239000011715 vitamin B12 Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 235000019156 vitamin B Nutrition 0.000 title abstract 2
- 239000011720 vitamin B Substances 0.000 title abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 4
- 229930003451 Vitamin B1 Natural products 0.000 abstract 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 2
- 229960003495 thiamine Drugs 0.000 abstract 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 2
- 235000010374 vitamin B1 Nutrition 0.000 abstract 2
- 239000011691 vitamin B1 Substances 0.000 abstract 2
- 235000019158 vitamin B6 Nutrition 0.000 abstract 2
- 239000011726 vitamin B6 Substances 0.000 abstract 2
- 229940011671 vitamin b6 Drugs 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003139 buffering effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest stały doustny trójskładnikowy preparat witamin z grupy B w postaci tabletek, zawierający jako substancje czynne witaminę B1, witaminę B6 i witaminę B12, przy czym witamina B12 jest stabilizowana w kompozycji zawierającej układ buforujący zapewniający stałe pH w zakresie 4,0 - 7,0, wielowodorotlenowy alkohol cukrowy i opcjonalnie, jedną lub więcej dopuszczalnych farmaceutycznie substancji pomocniczych. Preparat jest przeznaczony do leczenia wspomagającego w zaburzeniach układu nerwowego. Ujawniony jest również sposób wytwarzania preparatu o ustalonym składzie zawierającego witaminę B1, witaminę B6 i witaminę B12 w postaci tabletek.The subject of the application is a solid oral three-component preparation of B vitamins in the form of tablets, containing as active substances vitamin B1, vitamin B6 and vitamin B12, where vitamin B12 is stabilized in a composition containing a buffering system ensuring a constant pH in the range of 4.0 - 7, 0, a polyhydric sugar alcohol and optionally, one or more pharmaceutically acceptable excipients. The preparation is intended for adjunctive treatment in nervous system disorders. Also disclosed is a method for preparing a preparation with a fixed composition containing vitamin B1, vitamin B6 and vitamin B12 in the form of tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL443815A PL247034B1 (en) | 2021-02-04 | 2021-02-04 | Solid oral preparation of B vitamins containing a stabilized vitamin B12 composition and a method of producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL443815A PL247034B1 (en) | 2021-02-04 | 2021-02-04 | Solid oral preparation of B vitamins containing a stabilized vitamin B12 composition and a method of producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL443815A1 true PL443815A1 (en) | 2023-11-13 |
| PL247034B1 PL247034B1 (en) | 2025-04-28 |
Family
ID=88789809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL443815A PL247034B1 (en) | 2021-02-04 | 2021-02-04 | Solid oral preparation of B vitamins containing a stabilized vitamin B12 composition and a method of producing the same |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL247034B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083527A (en) * | 1998-11-05 | 2000-07-04 | Thistle; Robert | Breath mint with tooth decay and halitosis prevention characteristics |
| WO2010077878A1 (en) * | 2008-12-15 | 2010-07-08 | Fleming And Company, Pharmaceuticals | Rapidly dissolving vitamin formulation and methods of using the same |
| CN107510061A (en) * | 2017-10-17 | 2017-12-26 | 郑州瑞普生物工程有限公司 | A kind of sport nutrition chewable tablets and preparation method thereof |
-
2021
- 2021-02-04 PL PL443815A patent/PL247034B1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083527A (en) * | 1998-11-05 | 2000-07-04 | Thistle; Robert | Breath mint with tooth decay and halitosis prevention characteristics |
| WO2010077878A1 (en) * | 2008-12-15 | 2010-07-08 | Fleming And Company, Pharmaceuticals | Rapidly dissolving vitamin formulation and methods of using the same |
| CN107510061A (en) * | 2017-10-17 | 2017-12-26 | 郑州瑞普生物工程有限公司 | A kind of sport nutrition chewable tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| rejestrymedyczne.ezdrowie.gov.pl; numer pozwolenia 581/13; NEUROVIT Charakterystyka Produktu Leczniczego * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL247034B1 (en) | 2025-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE502005008880D1 (en) | LIPOSOMAL COMPOSITION CONTAINING AN ACTIVE SUBSTANCE FOR RELAXING SMOOTH MUSCULATURE, THE PREPARATION OF THIS COMPOSITION, AND THEIR THERAPEUTIC USE | |
| Zhong et al. | Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study | |
| MX2009001711A (en) | Sustained-release formulations of topiramate. | |
| AR062320A1 (en) | FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM | |
| MX344787B (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders. | |
| Tuite et al. | Recent developments in the pharmacological treatment of Parkinson’s disease | |
| MXPA04009123A (en) | Serotonin and catecholamine system segment optimization techonology. | |
| MX2022015629A (en) | USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER. | |
| ITMI20041689A1 (en) | NEW FORMULATIONS OF CONTROLLED RELEASE CONTAINING 5-HYDROXYTYRIPHOPHANE AND TRIPTOPHAN | |
| MX2024013020A (en) | Heteroaryl compounds for the treatment of pain | |
| NO20040536L (en) | Oral compositions for the treatment of scalp disease | |
| CL2021000882A1 (en) | Formulations and methods for treating chemotherapy-induced nausea and vomiting. | |
| WO2002100404A3 (en) | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes | |
| PL443815A1 (en) | Solid oral preparation of vitamins B containing a stabilized composition of vitamin B12 and method of its preparation | |
| CR20240514A (en) | Heteroaryl compounds for the treatment of pain | |
| ATE451340T1 (en) | DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| PL436880A1 (en) | Stabilized composition of vitamin B12 and a solid oral preparation of B vitamins and method of its preparation | |
| ES2526359T3 (en) | Oral galenic formulation comprising ketorolac and B vitamins, in which vitamin B6 is in an external layer separated from the rest of active ingredients | |
| Howland | Gabapentin for the treatment of substance use disorders | |
| MX2024015896A (en) | Pharmaceutical composition comprising a3 adenosine receptor agonist for treatment of psoriasis | |
| MXPA05008943A (en) | Serotonin and catecholamine system segment optimization technology. | |
| EA202092105A1 (en) | PHARMACEUTICAL COMPOSITION OR COMPOSITION OF A FOOD ADDITIVE BASED ON ALPHA-LACTALBUMIN | |
| MX2024012473A (en) | Modified release pharmaceutical formulations comprising deferiprone | |
| JP2005162713A (en) | Composition for oral administration | |
| WO2019203759A3 (en) | Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation. |